Lazarex Cancer Foundation

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2006

Legal Domicile

Principal Officer

Erin Miller

Tax Period

2025-01-01 to 2025-12-31

Lazarex Cancer Foundation, founded in 2006, is a small nonprofit in the Education sector that reported $865K in total revenue in fiscal year 2025. Revenue fell 66% from the prior year — a significant decline worth monitoring. Expenses of $2.0M exceeded revenue, resulting in a 137% operating deficit.

Mission

We strive to improve cancer health outcomes, FDA cancer clinical trial diversity and enrollment, and patient access to care by providing assistance with clinical trial navigation, reimbursing trial related travel costs, and partnering with at-risk communities to mobilize resources.

Program Service Accomplishments

Program 1

Expenses: $1,391,547

Lazarex Cancer Wellness Hub Program: Lazarex Cancer Wellness Hubs operated in Philadelphia through Drexel University and Penn Abramson, in Los Angeles through USC Norris, and in the San Francisco...

Lazarex Cancer Wellness Hub Program: Lazarex Cancer Wellness Hubs operated in Philadelphia through Drexel University and Penn Abramson, in Los Angeles through USC Norris, and in the San Francisco East Bay area in collaboration with Monument Crisis Center. The goal of the Lazarex Cancer Wellness Hub Program is to generate a replicable program that is place based, culturally appropriate, and community driven, that operates in at-risk communities of color across the continuum of cancer care to improve cancer health disparities and improve cancer health outcomes.

Program 2

Expenses: $62,841

Lazarex CARE Program: This program focuses on improving the outcome of cancer care for advanced stage cancer patients and the medically underserved by identifying FDA clinical trial options...

Lazarex CARE Program: This program focuses on improving the outcome of cancer care for advanced stage cancer patients and the medically underserved by identifying FDA clinical trial options, providing assistance with out-of-pocked travel expenses for clinical trial participation and a travel companion if needed, and by facilitating community outreach and engagement.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $816,745

Program Service Revenue $0

Investment Income $45,378

Other Revenue $3,178

TOTAL REVENUE $865,301

Expense Breakdown

Grants Paid $568,857

Salaries & Benefits $918,115

Fundraising Expenses $284,910

Program Expenses $1,454,388

Other Expenses $561,902

TOTAL EXPENSES $2,048,874

Year-over-Year Comparison

	2025	2024	Change
Revenue	$865,301	$2,555,804	-0.7%
Expenses	$2,048,874	$3,321,915	-0.4%
Net Income	$-1,183,573	$-766,111	+0.5%

Key Indicators

✓ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Marya Shegog	Health & Prog Dir	40.00		$110,000	$8,855	$118,855
Erin Miller	Director- Ops/Dev	40.00		$110,000	$8,100	$118,100
Clay Jackson	Chairman	2.00	Officer Director	$0	$0	$0
Kenny J Simansky	Vice President	2.00	Officer Director	$0	$0	$0
Kwame Boateng	CFO	2.00	Officer Director	$0	$0	$0
Darlene Chiang	Secretary	2.00	Officer Director	$0	$0	$0
Greg Francisco	Director	2.00	Director	$0	$0	$0
Karen Sessions	Director	2.00	Director	$0	$0	$0
Elaine MacNeilly	Director	2.00	Director	$0	$0	$0
Jackie Kent	Director	2.00	Director	$0	$0	$0
Samira Daswani	Director	2.00	Director	$0	$0	$0
Ahmad Alrawi	Director	2.00	Director	$0	$0	$0
Fabian Sandoval	Director	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$865,301	$2,048,874	$689,766	$-1,183,573
2024	$2,555,804	$3,321,915	$2,181,453	$-766,111
2023	$3,734,815	$6,230,037	$4,149,538	$-2,495,222
2022	$3,289,365	$4,988,333	$6,902,437	$-1,698,968
2021	$2,597,040	$3,280,353	$7,676,301	$-683,313
2020	$2,358,538	$2,871,446	$8,001,648	$-512,908
2019	$7,428,019	$2,721,863	$8,190,922	$4,706,156
2018	$3,006,859	$2,223,813	$3,328,204	$783,046